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Abstract
Introduction—Metabolomics technologies enable the identification of putative biomarkers for 
numerous diseases; however, the influence of confounding factors on metabolite levels poses a 
major challenge in moving forward with such metabolites for pre-clinical or clinical applications.
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Objectives—To address this challenge, we analyzed metabolomics data from a colorectal cancer 
(CRC) study, and used seemingly unrelated regression (SUR) to account for the effects of 
confounding factors including gender, BMI, age, alcohol use, and smoking.
Methods—A SUR model based on 113 serum metabolites quantified using targeted mass 
spectrometry, identified 20 metabolites that differentiated CRC patients (n = 36), patients with 
polyp (n = 39), and healthy subjects (n = 83). Models built using different groups of biologically 
related metabolites achieved improved differentiation and were significant for 26 out of 29 groups. 
Furthermore, the networks of correlated metabolites constructed for all groups of metabolites 
using the ParCorA algorithm, before or after application of the SUR model, showed significant 
alterations for CRC and polyp patients relative to healthy controls.
Results—The results showed that demographic covariates, such as gender, BMI, BMI2, and 
smoking status, exhibit significant confounding effects on metabolite levels, which can be 
modeled effectively.
Conclusion—These results not only provide new insights into addressing the major issue of 
confounding effects in metabolomics analysis, but also shed light on issues related to establishing 
reliable biomarkers and the biological connections between them in a complex disease.
Keywords
Seemingly unrelated regression; Colorectal cancer; Colorectal polyp; Metabolic profiling; 
Metabolomics; Targeted mass spectrometry; Clinical factors
1 Introduction
Colorectal cancer (CRC) affects both men and women of all ethnic groups around the world. 
As the second leading cause of cancer death, CRC is often found in people over 50 years 
old; an estimated 50,260 deaths is anticipated during 2017 in the United States alone (Siegel 
et al. 2017). It is widely accepted that the common risk factors of CRC include alcohol, 
colorectal polyps, family history, high-fat diets, smoking, and ulcerative colitis. CRC is 
highly treatable if detected at early stages, and therefore many screening tests (e.g., 
colonoscopy, flexible sigmoidoscopy, and stool-based tests) are performed for people at high 
risk (Lin et al. 2016). However, most of these tests are either invasive or expensive, which 
often make them difficult to implement in the clinic (Taylor et al. 2011). More recently, the 
U.S. FDA has approved Cologuard, a multi-target stool DNA test, and Epi proColon, a 
blood-based test for screening individuals at average-risk of CRC (Pickhardt 2016). The 
stool- and blood-based tests are increasingly becoming attractive primarily due to their non-
invasive nature. Each of these tests, however, exhibits different levels of performance to 
detect CRC and the precursor lesions. In view of these challenges, only 40% of CRC 
patients are diagnosed and treated at an early stage (Stages I–II), where relatively high (80–
90%) 5-year survival rates are common (Cancer Facts & Figures 2013). Therefore, it is 
crucial to develop sensitive, specific, inexpensive, and noninvasive methods that can be 
widely employed in regular clinical practice for people at high risk of CRC.
CRC, like most other cancers, is associated with altered cellular metabolism. For example, 
the well-known Warburg effect (Warburg 1956), involving increased glucose uptake and 
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lactate production, has been exploited for cancer detection through PET scanning. Other 
metabolically related mechanisms are providing new strategies to develop novel therapies 
and detection modalities (Wise and Thompson 2010; Jain et al. 2012; Sreekumar et al. 2009; 
DeBerardinis and Chandel 2016; Gross et al. 2010; Ward and Thompson 2012; Munoz-
Pinedo et al. 2012). The field of metabolomics simultaneously aims to identify altered 
metabolic pathways and mechanisms in diseases as well as robust and accurate biomarkers. 
To date, numerous metabolomics studies have focused on detecting biomarkers for CRC as 
well as altered metabolism (Qui et al. 2009; Nishiumi et al. 2012; Tan et al. 2013; Denkert et 
al. 2008; Chan et al. 2008; Ma et al. 2009; Li et al. 2013; Ritchie et al. 2010, 2013). A few 
metabolomics studies have also focused on identifying metabolite biomarkers for polyp 
patients, who are considered at high risk for developing CRC (Eisner et al. 2013; Zhu et al. 
2014). Depending on the biological samples and the analytical technique used in these 
studies, distinct sets of distinguishing biomarkers for CRC have been derived. It is, however, 
increasingly realized that the metabolite profiles are impacted by many factors such as 
gender, age, BMI, smoking, alcohol consumption, etc. The derived disease biomarkers are 
often confounded by one or more of these factors and hence often fail in validation studies. 
Thus, in general, the effect of confounding factors is a major challenge for metabolomics-
based biomarker discovery research.
Despite the critical need, currently, efforts to account for the contributions from numerous 
confounding factors in biomarker discovery are limited. Recently, in an effort to address this 
challenge, we utilized a powerful statistical approach, seemingly unrelated regression (SUR) 
(Zellner 1962; Aiken and West 1991; Ahrens 1971) to model the effects of such 
confounding factors, which thereby allowed an investigation of serum metabolites that could 
differentiate polyp patients and healthy controls (Chen et al. 2015). In the present study, we 
have extended this concept to unravel the confounding effects using a significantly larger 
pool of metabolites from three groups of subjects. We have used SUR to analyze metabolites 
measured using targeted mass spectrometry to compare patients with CRC or polyps and 
healthy controls. SUR analysis identified a number of metabolites, groups of biologically 
related metabolites and their correlations that are distinct as well as statistically significant 
among three sets of samples (e.g., CRC, patients with polyps, and healthy controls). 
Considering that conventionally used multivariate statistical analysis methods such as 
logistic regression and partial least squares-discriminant analysis are challenged by the large 
effects of confounding factors that can override subtle changes in metabolite levels due to 
diseases, SUR promises new avenues for addressing the dominant confounding effects in the 
metabolomics field.
2 Materials and methods
2.1 Patient samples
This study utilized metabolite data obtained from a previous study and the materials and 
methods are described in greater detail in the published report (Zhu et al. 2014). Briefly, a 
total of 158 serum samples from CRC patients (n = 36), polyp patients (n = 39), and healthy 
controls (n = 83), which represented a subset of the original samples that had full clinical 
information available were utilized for this study. Recruitment of patients and blood 
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collections were made as per the approved Institutional Review Board protocols from 
Purdue University and Indiana University School of Medicine. All consenting participants 
undergoing colonoscopy or CRC surgery were evaluated, and blood samples from the 
patients were obtained after overnight fasting and bowel preparation prior to their procedure. 
Each blood sample was allowed to clot for 45 min, centrifuged at 1500 g for 10 min, the 
serum (upper layer) was aliquoted into cryo-vials and stored at −80 °C until analysis.
2.2 Solvents and chemicals
Acetonitrile, ammonium acetate, and acetic acid were purchased from Fisher Scientific 
(Pittsburgh, PA). Standard compounds used for confirming the measured metabolites were 
purchased from Sigma-Aldrich (Saint Louis, MO) or Fisher Scientific (Pittsburgh, PA) (Zhu 
et al. 2014). Isotope labeled internal standards (L-tyrosine-13C2 and sodium-L-lactate-13C3) 
were purchased from Cambridge Isotope Laboratories (Tewksbury, MA). The purities of 
unlabeled standards were >95%, whereas the purities of the two 13C labeled compounds 
were >99%.
2.3 Sample preprocessing
Frozen samples were thawed at room temperature and 50 μL of each serum sample was 
placed in a 2 mL Eppendorf vial (Fisher Scientific). To precipitate proteins, methanol (150 
μL) was added and the mixture was vortexed for 2 min and kept at −20 °C for 20 min. Next, 
the mixture was centrifuged at 20,800 g for 10 min, and the supernatant was collected into a 
new Eppendorf vial. To recover any metabolites left in the protein pellet, each pellet was 
mixed with 300 μL methanol, vortexed for 10 min, centrifuged at 20,800 g for 10 min and 
the supernatant was pooled with that collected after the first centrifugation. The solution was 
then dried using a Vacufuge Plus evaporator (Eppendorf, Hauppauge, NY), reconstituted in a 
500 μL solution of 5 mM ammonium acetate in 40% water/60% acetonitrile +0.2% acetic 
acid containing two labeled internal standards, 5.13 μM L-tyrosine-13C2 and 22.5 μM 
sodium-L-lactate-13C3 (Cambridge Isotope Laboratory, Tewksbury, MA). The samples were 
filtered through 0.45 μm PVDF filters (Phenomenex, Torrance, CA) and used for MS 
analysis. A quality control (QC), which was a pooled serum sample from all three groups of 
subjects was also processed and prepared following the same procedure as used for 
individual samples and analyzed with the patients samples once every 10 patient samples.
2.4 Targeted mass spectrometry analysis
All samples were subjected to LC-MS/MS analysis using two hydrophilic interaction 
chromatography SeQuant ZIC-cHILIC columns (150 × 2.1 mm, 3.0 μm particle size, Merck 
KGaA, Darmstadt, Germany) connected in parallel and an AB Sciex QTrap 5500 mass 
spectrometer (AB Sciex, Toronto, ON, Canada) equipped with an electrospray ionization 
(ESI) source. A total of 158 MRM transitions were targeted (99 in negative ion mode and 59 
in positive ion mode), and 113 metabolites could be measured in the serum samples with 
sufficient signal-to-noise and very few or no missing data.
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2.5 Data preprocessing
The original data set was filtered to obtain samples that had values for all of the 
demographical and clinical variables under investigation (i.e., no missing values), leading to 
158 individuals with 36 CRC patients, 39 polyp patients and 83 healthy controls. The data 
were standardized by normalization to average QC values (n ≥ 5 per batch) on a metabolite 
by metabolite basis to account for minor instrument drift during the 12day acquisition.
2.6 Data analysis using SUR
The SUR analysis that generalizes linear regression models for multiple response variables 
was originally proposed more than half a century ago (Zellner 1962). As illustrated in our 
recent paper (Chen et al. 2015), SUR consists of multiple regression equations, with each 
equation providing one response variable (the level of a metabolite). In this study, the SUR 
model was applied to test the effect of diagnosis on levels of metabolites by including the 
three sets of samples from CRC, polyp patients, and healthy controls. First, a SUR model 
was built to investigate how levels of all 113 metabolites were influenced by the following 
demographic variables: age, age2, gender, BMI, BMI2, smoking status, alcohol status, 
diagnosis, as well as the interactions between diagnosis and the other covariates. In all, a 
total of 15 covariates in each of the 113 regression equations was involved in the SUR 
model. The SUR model for each of the 113 metabolites can be written as:
Yi j = βo j + Xi1β1 j + Xi2β2 j +…+ Xipβp j + εi j
where Yij is the jth metabolite level for the ith individual, Xik denotes the value of the kth 
covariate of the ith individual, and εij is the error term which follows N 0, σ j2 . The error 
terms are independent across individuals, but may be correlated across the equations. 
Backward variable elimination (BVE) was then performed to remove insignificant covariates 
(i.e., those with p-value ≥0.05). Demographic covariates showing significant interactions 
with diagnosis were included in all linear regression models on each of the 113 metabolites 
in subsequent analysis. In addition to individual metabolites subjected to multiple linear 
regression analysis, we also partitioned all metabolites into 29 biologically related groups 
based on their presence in predefined metabolic pathways (glycolysis, TCA cycle, purine 
metabolism, amino acid metabolism, etc.), and further applied SUR analysis to evaluate the 
effect of disease risk on different groups of metabolites. The ParCorA algorithm (Schafer 
and Strimmer 2005) was used to construct networks of metabolites in CRC, polyp patients 
and healthy subjects separately for all groups of metabolites both before and after using 
SUR to account for the effect of confounding variables. Using the ParCorA algorithm, the 
Pearson correlation coefficient between each pair of metabolites within the same group was 
calculated, and an edge was built between two metabolites if the p-value of the correlation 
was less than a pre-specified significance level (p < 0.01).
3 Results
This study utilized targeted LC-MS/MS based metabolite data previously obtained for 
human serum samples from 158 individuals with CRC (n = 36), patients with colorectal 
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polyps (n = 39) or healthy controls (n = 83). Patient demographic and clinical information, 
including smoking and alcohol status are shown in Supporting Information Table S1. Using 
LC-MS/MS analysis, which involved utilizing a pre-established list of mass values for 
parent and fragment ions for each metabolite, relative concentrations of 158 different 
metabolites were measured. Of these, 113 metabolites were detected and quantified reliably 
as assessed by a lower coefficient of variation (CV) values for these metabolites (CV median 
8%, ranging from 5 to 31%, with ~80% metabolites having CV < 15%), and no missing 
values. The quantified metabolites represented diverse biochemical classes and over 25 
distinct metabolic pathways.
3.1 SUR analysis
In the SUR analysis we performed BVE of the predictors, using the 113 metabolites and the 
demographic variables age, age2, gender, BMI, BMI2, smoking status, alcohol status, 
diagnosis, as well as the interactions between diagnosis and all the other seven covariates. 
BVE was employed to remove insignificant covariates prior to further analysis. Table 1 
shows the results of BVE for predictors, which indicates, however, that all covariates were 
significant with p-values < 0.05. Hence, all covariates were included in subsequent analysis. 
Using these predictors, each metabolite was analyzed separately using multivariate linear 
regression. The results of the linear regression analysis for testing the diagnosis and its 
interaction with other demographic variables for all 113 metabolites showed that 20 out of 
the 113 metabolites were significant for diagnosis (Table 2, adjusted p < 0.05). Full results 
for the 113 metabolites are shown in Supporting Information Table S2. Among the 20 
metabolites with adjusted p < 0.05, several had quite low p-values, with aspartic acid being 
the most significant, followed by glyceraldehyde, xanthine, xanthosine, orotate, 
hydroxyproline/aminolevulinate and hippuric acid (Table 2).
SUR analysis was then performed on subsets of the metabolites defined by their presence in 
29 different metabolically related groups (Table 3). This SUR analysis showed that 
metabolites within the same group were significantly different among CRC, polyp patients 
and healthy controls for all 29 groups except three. The three groups that did not show 
significant differences were propionate metabolism consisting of four detected metabolites, 
bile acid metabolism consisting of four metabolites, and ketone bodies consisting of two 
metabolites. To further investigate the effects of diagnosis and demographic variables on the 
bile acid metabolism group, we built two SUR models, with the predictor being diagnosis 
only for one model and demographic variables only for the other model, to test the effects of 
diagnosis and demographic variables separately. The p-value for testing the diagnosis effect 
was 0.913 and the p-value for testing the effect of demographic variables was 3.16e−08. 
Table 3 lists the 29 groups along with the number of metabolites in each group, the pathway 
each group represents and the corresponding p-value obtained from the SUR analysis. 
Names of the metabolites in each group are listed in the Supporting Information Table S3. 
Among the seven metabolites that showed highly significant differences in the individual 
metabolite analysis (Table 2), aspartic acid was present in 6 groups, glyceraldehyde and 
hippuric acid were present in one group each, and xanthine, xanthosine, orotate and 
hydroxyproline/aminolevulinate were present in two groups each, as shown in the 
Supporting Information Table S3. Interestingly, all the groups in which these highly 
Chen et al. Page 6
Metabolomics. Author manuscript; available in PMC 2019 February 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
significant metabolites were present (groups 3, 4, 5, 10, 15, 16, 17, 18, 19, 20 and 23 in 
Table 3) also exhibited very high levels of significance for diagnosis as shown by their very 
low p-values.
3.2 Correlation analysis
Differences in terms of correlated metabolite networks were also observed in CRC, polyp 
patients and healthy subjects for all groups of metabolites before and after using SUR to 
account for the effects of confounding variables. The number of significant correlations 
(connections) between metabolites varied between healthy individuals, patients with polys 
and CRC patients. It is interesting to observe that the complexity of constructed networks of 
metabolites in some groups was reduced from healthy subjects to polyp patients, and further 
reduced for CRC patients. For example, as shown in Fig. 1, the total number of connections 
of constructed networks of metabolites in Group 14 is 17, 13, and 7 for healthy subjects, 
polyp patients, and CRC patients, respectively. Overall, for the Group 14 metabolites, there 
was a loss of correlation, in this case from an average of 0.36 for healthy subjects to an 
average of 0.24 for CRC patients, which results in a reduced number of connections. Of 
course, many of those correlations still exist, they are just smaller and therefore do not reach 
the cutoff value.
Table 4 summarizes the number of connections in the constructed networks of metabolites, 
as well as the average value of the correlation coefficient between metabolites in CRC, polyp 
patients and healthy subjects for all groups of metabolites both before and after using SUR 
to account for the effects of confounding variables. The results show that while the 
constructed networks of metabolites for a few groups remain the same before and after using 
SUR to account for the effects of confounding variables, the networks for most groups 
exhibited differences before and after using SUR to account for the effects of confounding 
variables. For example, while the constructed network of metabolites for Group 15 has 18, 9 
and 5 connections in healthy controls, polyp patients and CRC before using SUR (see Fig. 
2), respectively, the number of connections changed to 14, 10 and 9 after using SUR to 
account for the effects of confounding variables (Fig. 2). In addition, using SUR to account 
for the effects of confounding variables had an effect on the average value of correlation 
between metabolites in CRC, polyp patients and healthy subjects for most groups of 
metabolites. For Group 15, the average value of correlation between metabolites in CRC, 
polyp patients and healthy subjects was 0.18, 0.11 and 0.18, respectively, before using SUR, 
while the values change to 0.15, 0.16, and 0.18 after using SUR (Table 4). While the effect 
of SUR on some metabolite groups was observed to be sizeable, the overall effect of SUR on 
the median number of connections and median correlation values across all groups was 
relatively small.
4 Discussion
Advances in metabolomics technologies have enabled the analysis of a wider pool of 
metabolites with high fidelity and led to the identification of numerous metabolites that are 
putative biomarkers for the prediction or the diagnosis of numerous diseases. However, 
confounding effects pose a major challenge for reproducibility, validation and ultimately the 
Chen et al. Page 7
Metabolomics. Author manuscript; available in PMC 2019 February 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
utility of such potential biomarkers for pre-clinical or clinical applications. This challenge, 
in general, represents a major bottleneck in biomarker discovery for the metabolomics field. 
Therefore, it is increasingly becoming a critical priority that such confounding factors be 
taken into account in the effort to identify and validate reliable biomarkers. In the current 
study, we have used a SUR regression model to analyze metabolite data from CRC patients, 
polyp patients and healthy controls while accounting for the effects of some major 
confounding variables including gender, BMI, age, and alcohol/smoking use. Previously, 
SUR analysis was applied for genome-wide association (Saint-Pierre et al. 2011) and 
nutritional epidemiology studies (Carroll et al. 2006). We recently proposed that the SUR 
model could be useful for metabolomics applications, and demonstrated how SUR analysis 
of NMR detected metabolites could differentiate polyp patients from healthy controls (Chen 
et al. 2015). In the present study, we have used a larger pool of metabolites (>100) obtained 
using highly sensitive targeted LC-MS. The SUR model was applied to test diagnosis by 
including three levels of the diagnosis variable: CRC, polyps or healthy control. Even after 
correction for the potentially confounding clinical factors, many metabolites (20) were found 
to be significant for the diagnosis (see Table 3). These results signify the magnitude of the 
confounding effects as well as the ability of the SUR models to account for the contributions 
of such effects.
Detected metabolites in this study span more than 25 metabolic pathways, including major 
pathways such as the TCA cycle, glycolysis, gluconeogenesis, amino acid metabolism, urea 
cycle, purine, pyrimidine and nucleotide metabolism, carbohydrate and lipids pathways. To 
test the differentiating ability of such metabolic pathways, we have also investigated how 
major metabolic pathways are affected by the confounding variables. We therefore grouped 
metabolites based on their known association with specific metabolic pathways and 
subjected each group to SUR analysis. In line with the performance of the individual 
metabolites (Table 2), the low p-values observed for most of the biological groups indicate 
the strong differentiating ability of the groups of metabolites (Table 3).
Colorectal polyps represent a major risk factor for the later development of CRC. The ability 
to distinguish patients with polyps from healthy controls as well as CRC is critical for the 
prediction and diagnosis of CRC. With the goal of visualizing metabolic distinctions among 
CRC, polyp patients and healthy controls, we constructed networks of correlated metabolites 
using different groups of metabolites and the ParCorA algorithm. Calculation of the 
correlations was performed before and after applying the SUR model. The results show that 
both the number of connections and the average value of correlations were different among 
CRC, polyp patients and healthy controls, which indicate differences in the altered 
metabolism in the patients and control groups (Table 4). In some cases, the results were 
dramatically different (see Fig. 1). In addition, after SUR analysis, both the number of 
connections and the average correlations were altered for all but a few groups of metabolites, 
which indicates the extensive influence of confounding variables on metabolite levels.
The metabolites that were found to be significant (p < 0.05) for testing the diagnosis (Table 
2) represent many metabolic pathways including glycolysis, TCA cycle, amino acids, 
nucleotide and lipids pathways. Alteration of these pathways is well known in cancer. For 
example the Warburg effect that affects glycolysis and TCA cycle pathways for energy 
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generation in cancer cells is a well-known characteristic of cancer metabolism (Warburg 
1956). Individually, 17 metabolites that were found to be significant for testing the 
diagnosis, based on SUR analysis, were previously shown to have links with CRC and 
colorectal polyp (Zhu et al. 2014). It was shown that aspartic acid, glutamine, lysine, 
methionine, histidine, hippuric acid, alpha-ketoglutarate, glyceraldehyde, hydroxyproline/
aminolevulinate, linoleic acid, linolenic acid and 2′-deoxyuridine distinguish CRC and 
healthy controls as well as CRC and polyps. Similarly, cystathionine was shown to be 
associated with CRC and healthy controls; alanine, xanthine and orotate were shown to 
distinguish CRC and polyps; and glucose-1,6-bisphosphate (G16BP) was shown to 
distinguish between polyp patients and healthy controls.
Interestingly, among the metabolites detected by SUR analysis (Table 2), three metabolites 
including phenylalanine, xanthosine and epinephrine were unique in that their association 
with polyps is shown here for the first time. The fact that these metabolites were not found 
to be significant in the absence of SUR analysis (Zhu et al. 2014) indicates that the three 
metabolites are strongly influenced by the demographical variables. The association of 
phenylalanine indicates altered amino acid metabolism in cancer and is in accordance with 
many other amino acids that are associated with the disease. Xanthosine is associated with 
purine metabolism and indicates altered purine metabolism that is further supported by the 
observed significant changes in xanthine, which is also associated with purine metabolism. It 
may be noted that about half of the metabolites that were previously shown to be associated 
with CRC (Zhu et al. 2014) lost their significance after SUR analysis, which further signifies 
the magnitude of contributions from the demographic covariates. Nevertheless, some of this 
reduction may be due to the smaller number of samples analyzed in this study.
Differentiating metabolites in serum identified based on the present SUR analysis were also 
compared with bio-marker candidates obtained in a number of other, earlier studies that used 
the same type of biospecimen, serum. Supplemental Information Table S4 provides a list of 
differentiating metabolites that are the same and different from those identified in the present 
study. Studies by Li et al. (Li et al. 2013) and (Ritchie et al. 2010, 2013) were focused on 
serum lipids and hence none of the biomarkers identified had any commonality with those in 
the present study. In addition to our own prior work (Zhu et al. 2014), three studies identified 
several aqueous metabolites that differentiated colorectal cancer from controls. In the GC-
MS based study by Nishiumi et al., one out of a total four differentiating metabolites was 
same as that identified by SUR analysis (Nishiumi et al. 2012); in the study by Qiu et al., 
four out of thirty-three differentiating metabolites were the same (Qiu et al. 2009); and in the 
study by Tan et al., seven out of seventy-two metabolites were same as that identified by 
SUR analysis (Tan et al. 2013). Interestingly, phenylalanine, one of the three significant 
metabolites revealed after SUR analysis was also identified by two other studies, and 
xanthosine was identified by one other study (see Supplementary Table S4). However, a 
large number of differentiating metabolites from the earlier studies were different. The use 
of multiple analytical platforms that detect different pools of metabolites can explain such 
differences to some extent. Nevertheless, SUR analysis eliminated many metabolites 
including 3-hydroxybuturate, fumarate, creatinine, and pro-line that were shown to be 
differential metabolites by many studies (including our own prior study); in some cases SUR 
revealed other metabolites to have differentiating potential as discussed above. These 
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findings further highlight the contribution of potential confounding effects in metabolomics 
studies.
5 Conclusion
Our results indicate that demographic covariates such as gender, BMI, BMI2, and smoking 
status exhibit significant confounding effects on metabolite levels as well as correlations 
between metabolites in the same biological group, which need to be taken into account in 
order to obtain a better representation of the effects of disease on metabolite levels. 
Importantly, biomarker discovery can be confounded by one or more of these factors. In this 
work, we used SUR to model how metabolites levels as well as their correlations are 
affected by several clinical variables, and investigated the ability of serum metabolites to 
differentiate CRC, polyp patients and healthy controls after accounting for the effects of 
confounding variables. These results may promise new avenues for addressing the often 
dominant confounding effects in the metabolomics field.
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Fig. 1. 
Comparison of the number of significant correlations as indicated by the connections 
between metabolites for the constructed networks of Group 14 metabolites in cancer, polyp 
patients and healthy subjects. An overall reduction of the number of significant correlations 
is observed from healthy control to CRC
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Fig. 2. 
Comparison of the number of significant correlations as indicated by the connections 
between metabolites for the constructed networks of Group 15 metabolites in cancer, polyp 
patients and healthy subjects. SUR analysis affects a number of the significant correlations 
between metabolites, but the overall pattern of higher correlation between metabolites in 
healthy controls continues to hold
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Table 1
The results of BVE for predictors including age, age2, gender, BMI, BMI2, smoking status, alcohol status, 
diagnosis, as well as the interactions between diagnosis and other covariates
Selected effects p value
Age 0
Age2
Gender 0
BMI 0
BMI2
Smoking
Alcohol 9.45e−14
Diagnosis 0
Diagnosis × age 0
Diagnosis × age2
Diagnosis × gender 0
Diagnosis × BMI 0
Diagnosis × BMI2
Diagnosis × smoking 0
Diagnosis × alcohol 0
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Table 2
Metabolites found to be significant (p < 0.05) for testing the diagnosis based on linear regression analysis 
using the predictors selected from BVE
Metabolite p value Adjusted p value
Alanine 1.53e−04 0.0022
Aspartic acid 5.09e−08 2.88e−06
2’-Deoxyuridine 0.0085 0.048
Glutamine 4.33e−04 0.0049
Histidine 8.30e−04 0.0078
Lysine 0.0042 0.028
Methionine 0.0017 0.014
Phenylalanine 0.0055 0.033
Alpha-ketoglutaric acid 0.0026 0.02
G16BP 0.0013 0.011
Glyceraldehyde 6.22e−10 7.03e−08
Cystathionine 3.88e−04 0.0049
Epinephrine 6.68e−04 0.0069
Hydroxyproline/Aminolevulinate 1.19e−06 2.23e−05
Hippuric acid 4.43e−06 7.15e−05
Linoleic acid 0.0052 0.033
Linolenic acid 0.0037 0.026
Orotate 1.15e−06 2.23e−05
Xanthine 2.13e−07 8.01e−06
Xanthosine 3.31e−07 9.34e−06
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